7.70 USD
▼-1.30-14.44%
盘后 5.36 0.00%
2026-09-16
市值
$14.09M
市盈率
—
EPS
-13.22
股息率
—
52 周区间
4.91 – 34.25
成交量
101.78K
Beta
0.91
目标价
—
52W 低 4.9152W 高 34.25
价格走势
公司简介
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand...